HCP Live: Heart Trials Podcast: DAPA-HF, with Mikhail Kosiborod, MD

May 17, 2021

Heart Trials, a specialty podcast series from HCPLive, talked to Mikhail Kosiborod, MD, director of Cardiometabolic Research at Saint Luke's Mid America Heart Institute, and professor of Medicine at the University of Missouri-Kansas City, about the DAPA-HF trial, as well as the application of dapagliflozin in COVID-19 patients with respiratory failure from the DARE-19 trial.

Listen to the full podcast below and read the article: DAPA-HF, with Mikhail Kosiborod, MD

Related Content

DARE-19 Phase III trial did not reach statistical significance for primary endpoints, but showed numerically fewer events of new or worsened organ dysfunction or death in patients hospitalized with COVID-19
Saint Luke's Mid America Heart Institute shared detailed trial results in a Late Breaking Clinical Trials Session at the American College of Cardiology Scientific Session.
Healio: DARE-19: No significant decrease in major events; dapagliflozin well treated in COVID-19
Dr. Mikhail Kosiborod presented findings of the DARE-19 Trial at the ACC Scientific Session.
Saint Luke’s Researchers Again Take Center Stage at Global Cardiology Conference
Saint Luke’s Mid America Heart Institute to share detailed trial results at American College of Cardiology Scientific Session May 15-17.